The influence of acute varenicline administration on smoking and eating behavior in humans

William W. Stoops; Andrea R. Vansickel; Paul E.A. Glaser; Craig R. Rush

doi:10.1016/j.pbb.2008.07.001

The influence of acute varenicline administration on smoking and eating behavior in humans

William W. Stoops, Andrea R. Vansickel, Paul E.A. Glaser, Craig R. Rush

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Varenicline (Chantix®) is a novel smoking-cessation agent that acts at a number of nicotinic acetylcholine receptors. The aim of this study was to determine the behavioral effects of acute varenicline administration in human subjects. The effects of doses of varenicline (0.5, 1 and 2 mg), methylphenidate (40 mg; positive control) and placebo were assessed in 8 (7 males, 1 female) cigarette smokers. Staggered, double blind dosing was used to examine eating and smoking behavior during the peak effects of varenicline and methylphenidate. Starting at the published time to peak plasma levels of these drugs, subjects were allowed to smoke and eat ad libitum for 4 h. Acute varenicline was devoid of behavioral effects. Methylphenidate produced prototypical stimulant-like effects (e.g., increased smoking behavior; decreased caloric intake). The present results indicate that acute varenicline administration does not alter smoking behavior although the low number of subjects limits the ability to detect small effects. Future research should examine the effects of chronic varenicline on smoking and eating behavior in humans, particularly using operant techniques to determine whether varenicline alters the reinforcing effects of cigarettes and food in humans.

Original language	English
Pages (from-to)	165-169
Number of pages	5
Journal	Pharmacology Biochemistry and Behavior
Volume	91
Issue number	1
DOIs	https://doi.org/10.1016/j.pbb.2008.07.001
State	Published - Nov 2008

Bibliographical note

Funding Information:
This work was supported by seed funds from the Departments of Behavioral Science (to WWS) and Psychiatry (to CRR) at the University of Kentucky College of Medicine. The authors declare no financial relationships with persons or organizations that could be perceived to bias the work described herein. We would like to thank Frances Wagner, R.N. for excellent medical supervision and Neena Khanna, Ph.D. for excellent technical supervision of this study.

Funding

This work was supported by seed funds from the Departments of Behavioral Science (to WWS) and Psychiatry (to CRR) at the University of Kentucky College of Medicine. The authors declare no financial relationships with persons or organizations that could be perceived to bias the work described herein. We would like to thank Frances Wagner, R.N. for excellent medical supervision and Neena Khanna, Ph.D. for excellent technical supervision of this study.

Funders	Funder number
Departments of Behavioral Science
University of Kentucky College of Medicine

Keywords

Eating
Humans
Methylphenidate
Smoking
Varenicline

ASJC Scopus subject areas

Biochemistry
Toxicology
Pharmacology
Clinical Biochemistry
Biological Psychiatry
Behavioral Neuroscience

Access to Document

10.1016/j.pbb.2008.07.001

Cite this

@article{c77c7401866b4d239d9ee18a89874ac8,

title = "The influence of acute varenicline administration on smoking and eating behavior in humans",

abstract = "Varenicline (Chantix{\textregistered}) is a novel smoking-cessation agent that acts at a number of nicotinic acetylcholine receptors. The aim of this study was to determine the behavioral effects of acute varenicline administration in human subjects. The effects of doses of varenicline (0.5, 1 and 2 mg), methylphenidate (40 mg; positive control) and placebo were assessed in 8 (7 males, 1 female) cigarette smokers. Staggered, double blind dosing was used to examine eating and smoking behavior during the peak effects of varenicline and methylphenidate. Starting at the published time to peak plasma levels of these drugs, subjects were allowed to smoke and eat ad libitum for 4 h. Acute varenicline was devoid of behavioral effects. Methylphenidate produced prototypical stimulant-like effects (e.g., increased smoking behavior; decreased caloric intake). The present results indicate that acute varenicline administration does not alter smoking behavior although the low number of subjects limits the ability to detect small effects. Future research should examine the effects of chronic varenicline on smoking and eating behavior in humans, particularly using operant techniques to determine whether varenicline alters the reinforcing effects of cigarettes and food in humans.",

keywords = "Eating, Humans, Methylphenidate, Smoking, Varenicline",

author = "Stoops, {William W.} and Vansickel, {Andrea R.} and Glaser, {Paul E.A.} and Rush, {Craig R.}",

note = "Funding Information: This work was supported by seed funds from the Departments of Behavioral Science (to WWS) and Psychiatry (to CRR) at the University of Kentucky College of Medicine. The authors declare no financial relationships with persons or organizations that could be perceived to bias the work described herein. We would like to thank Frances Wagner, R.N. for excellent medical supervision and Neena Khanna, Ph.D. for excellent technical supervision of this study.",

year = "2008",

month = nov,

doi = "10.1016/j.pbb.2008.07.001",

language = "English",

volume = "91",

pages = "165--169",

number = "1",

}

TY - JOUR

T1 - The influence of acute varenicline administration on smoking and eating behavior in humans

AU - Stoops, William W.

AU - Vansickel, Andrea R.

AU - Glaser, Paul E.A.

AU - Rush, Craig R.

N1 - Funding Information: This work was supported by seed funds from the Departments of Behavioral Science (to WWS) and Psychiatry (to CRR) at the University of Kentucky College of Medicine. The authors declare no financial relationships with persons or organizations that could be perceived to bias the work described herein. We would like to thank Frances Wagner, R.N. for excellent medical supervision and Neena Khanna, Ph.D. for excellent technical supervision of this study.

PY - 2008/11

Y1 - 2008/11

N2 - Varenicline (Chantix®) is a novel smoking-cessation agent that acts at a number of nicotinic acetylcholine receptors. The aim of this study was to determine the behavioral effects of acute varenicline administration in human subjects. The effects of doses of varenicline (0.5, 1 and 2 mg), methylphenidate (40 mg; positive control) and placebo were assessed in 8 (7 males, 1 female) cigarette smokers. Staggered, double blind dosing was used to examine eating and smoking behavior during the peak effects of varenicline and methylphenidate. Starting at the published time to peak plasma levels of these drugs, subjects were allowed to smoke and eat ad libitum for 4 h. Acute varenicline was devoid of behavioral effects. Methylphenidate produced prototypical stimulant-like effects (e.g., increased smoking behavior; decreased caloric intake). The present results indicate that acute varenicline administration does not alter smoking behavior although the low number of subjects limits the ability to detect small effects. Future research should examine the effects of chronic varenicline on smoking and eating behavior in humans, particularly using operant techniques to determine whether varenicline alters the reinforcing effects of cigarettes and food in humans.

AB - Varenicline (Chantix®) is a novel smoking-cessation agent that acts at a number of nicotinic acetylcholine receptors. The aim of this study was to determine the behavioral effects of acute varenicline administration in human subjects. The effects of doses of varenicline (0.5, 1 and 2 mg), methylphenidate (40 mg; positive control) and placebo were assessed in 8 (7 males, 1 female) cigarette smokers. Staggered, double blind dosing was used to examine eating and smoking behavior during the peak effects of varenicline and methylphenidate. Starting at the published time to peak plasma levels of these drugs, subjects were allowed to smoke and eat ad libitum for 4 h. Acute varenicline was devoid of behavioral effects. Methylphenidate produced prototypical stimulant-like effects (e.g., increased smoking behavior; decreased caloric intake). The present results indicate that acute varenicline administration does not alter smoking behavior although the low number of subjects limits the ability to detect small effects. Future research should examine the effects of chronic varenicline on smoking and eating behavior in humans, particularly using operant techniques to determine whether varenicline alters the reinforcing effects of cigarettes and food in humans.

KW - Eating

KW - Humans

KW - Methylphenidate

KW - Smoking

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=50349094783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349094783&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2008.07.001

DO - 10.1016/j.pbb.2008.07.001

M3 - Article

C2 - 18675291

AN - SCOPUS:50349094783

SN - 0091-3057

VL - 91

SP - 165

EP - 169

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

IS - 1

ER -

The influence of acute varenicline administration on smoking and eating behavior in humans

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this